Budget Amount *help |
¥44,720,000 (Direct Cost: ¥34,400,000、Indirect Cost: ¥10,320,000)
Fiscal Year 2014: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2013: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2012: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2011: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2010: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
Outline of Final Research Achievements |
We constructed a HD-Ad.AAV BTK targeting vector that is composed of the genomic sequence containing BTK exons 6-19, TIMM8A and GFP/hygromycin resistant gene. By using HD-Ad.AAV. BTK vector, we found that the targeting in the BTK gene occurred in 4 among 755 hygromycin-resistant BFU-E colonies differentiated from the cord blood CD34+ cells. Importantly, the gene targeting was also observed in CD19+ lymphoid progenitor cells that could be differentiated from the homologous recombinants of CD34+ cells. Our study shows the potential of HD-Ad.AAV. BTK vector for the BTK gene therapy by homologous recombination in hematopoietic stem cells.
|